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Abstract 
Anti-retroviral drugs can reduce the infectiousness of people living with HIV by about 96%—‘treatment as prevention’ 
or TasP—and can reduce the risk of being infected by an HIV positive person by about 70%—‘pre-exposure 
prophylaxis’ or PrEP—raising the prospect of using anti-retroviral drugs to stop the epidemic of HIV. The question as 
to which is more effective, more affordable and more cost effective, and under what conditions, continues to be debated 
in the scientific literature. Here we compare TasP and PreP in order to determine the conditions under which each 
strategy is favourable. This analysis suggests that where the incidence of HIV is less than 5% or the risk-reduction 
under PrEP is less than 50%, TasP is favoured over PrEP; otherwise PrEP is favoured over TasP. The potential for 
using PreP should therefore be restricted to those among whom the annual incidence of HIV is greater than 5% and 
TasP reduces transmission by more than 50%. PreP should be considered for commercial sex workers, young women 
aged about 20 to 25 years, men-who-have-sex with men, or intravenous drug users, but only where the incidence of 
HIV is high.   
Introduction 
The XIX International AIDS Conference held in 
Washington DC in 2012, was dominated by the prospect 
of ending the epidemic of HIV,1 and bringing about 
what Secretary of State Hilary Clinton called an ‘AIDS 
Free Generation’.2 The discussions were motivated by 
the realization that anti-retroviral therapy (ART) keeps 
people alive, renders them much less infectious, makes 
HIV-negative people much less likely to be infected, 
and stops vertical transmission. A still unresolved 
question concerns the relative impact and benefits of 
using ART to render HIV-positive people 
uninfectious—Treatment as Prevention or TasP—as 
compared to using ART to protect HIV-negative people 
from becoming infected—pre-exposure prophylaxis or 
PrEP.3-20 
 In 2012 the International Association of Physicians 
for AIDS Care published a consensus statement on the 
use of TasP and PrEP21 but did not consider in detail the 
conditions under which TasP should be favoured over 
PrEP and vice versa. For the purposes of this discussion 
we assume that: 
• Under TasP, people would be tested at regular 
intervals, start ART as soon as they are found to be 
HIV positive, and then maintained on ART for life.  
• Under PrEP, people would start ART as soon as they 
are thought to be at risk of HIV. If they remain HIV-
negative they would stay on ART until they are no 
longer at risk; if they become infected with HIV they 
would be switched to a different regimen, if 
necessary, and kept on ART for life.  
In both cases people would be visited at regular 
intervals: infected people would need to receive drugs 
and be monitored for compliance, viral rebound and 
drug resistance; uninfected people would need to 
receive drugs and be monitored for compliance under 
PrEP and tested for HIV under TasP. We will assume 
that requirements for support and testing under the two 
approaches are equivalent. The important comparison is 
therefore between the number of person years on ART 
after they become infected under TasP and the number 
of person years on ART both before they become 
infected but remain at risk and after they become 
infected under PrEP. 
 Here we only consider the individual benefit and do 
not include the long term impact on transmission. This 
analysis is therefore relevant to a situation in which we 
have a small group of people, or even an individual 
person who can be managed either under TasP or PrEP. 
Methods 
Let the annual incidence of HIV in the population under 
consideration be α. We assume 1) that PrEP reduces the 
risk that the person becomes infected by a factor of ρ so 
that the incidence among those on PrEP is β = ρα; 2) 
that they remain at risk for a time d after which they are 
no longer at risk where d could refer to the time for 
which women remain in sex-work or to the time for 
which people remain sexually active and at risk; 3) that 
the life expectancy of uninfected people and those on 
ART is l. 
 The two strategies are illustrated schematically in 
Figure 1. The blue line shows people who are receiving 
drugs under TasP. Those in areas B, C, D and E are on 
ART because they are HIV-positive; those in areas D 
and E are no longer at risk but are HIV-positive, having 
been infected earlier. The red line shows proportion of 
people who are receiving drugs under PrEP. Those in 
area A and B are receiving drugs while they are HIV-
negative; those in area C have become HIV-positive, in 
spite of being on PrEP; those in area E have acquired 
HIV but are no longer at risk and must be maintained on 
ART until they die.  
 From Figure 1 it is clear that the difference in the 
number of person years on ART under a policy of TasP 
as opposed to PrEP is determined by the relative sizes of 
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areas A and D since the other areas are common to both 
strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Proportion of people on ART under TasP (blue line) 
and PrEP (red line). A: people on PrEP only; B and C: people 
on TasP and PrEP; D: people on TasP only; E people on PreP 
and TasP. Here the duration of risk behaviour is d = 10 years 
and life-expectancy is l = 40 years after the start of risk 
behaviour. 
 The incidence of HIV without PrEP is α and with 
PrEP be β so that the relative risk of infection with PrEP 
is ρ = β/α . Then the areas in Figure 1 are: 
 ( )1 1 e dA αα −= −  1 
 ( )1 1 e dA B ββ −+ = −  2 
 ( )1 1 e dC d ββ −= − −  3 
 ( )( )e ed dD l d β α− −= − −  4 
 ( )( )1 e dE l d β−= − −  5 
The total number of person years on ART under PrEP is 
A+B+C+E and under TasP is B+C+D+E. 
Results 
We assume here that people are at risk of HIV for 10 
years and will live for 40 years after they are exposed to 
the risk of HIV infection. This would correspond, for 
example, to a situation in which young people are at risk 
from the age of 20 years to the age of 30 years and live 
to the age of 60 years. Alternatively, one might consider 
a women engaging in sex-work from the age of 20 to 30 
years and then stopping but continuing to live to the age 
of 60 years. 
 In Figure 2 the number of person years on ART 
under PrEP and under TasP is plotted as a function of 
the annual incidence of HIV without PrEP (horizontal 
axis) and the relative risk of infection if a person is on 
PrEP as compared to those that are not (vertical axis). 
The heavy black line shows the combinations of values 
where PrEP and TasP are equivalent. Above the black 
line TasP would lead to having fewer person years on 
ART; below the black line PrEP would lead to having 
fewer years on ART. If the annual incidence is about 
0.3%, say, indicated by the junction between the two 
green areas, then PrEP would lead to having 8 times as 
many person years on ART. If PrEP reduces incidence 
by less than 40% (relative risk > 0.6; peak of heavy 
black line in Figure 1) PrEP would always lead to an 
increase in the number of person years on ART. If the 
incidence of infection is less than 0.3% per year 
(intersection of heavy black line and horizontal axis) 
TasP would always be favoured over PreP. The best 
prospects for using PrEP would be when the annual 
incidence is about 20% (peak of the heavy black line in 
Figure 2). Even then PrEP would have to reduce the risk 
of HIV infection by 90% in order to halve the number 
of person years on ART (line separating pink and red 
areas in Figure 2.) 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Area plot of the ratio, R, of the number of person 
years on ART under PrEP compared to TasP. The horizontal 
axis gives the annual incidence of HIV without PrEP on a 
logarithmic scale; the vertical axis gives the relative risk of 
HIV infection for people on PrEP as compared to those that 
are not. Numbers in boxes give the value of R along each 
contour. Below the heavy black line PrEP is favoured; above 
the black line TasP is favoured. 
 
 
 
 
 
 
 
 
 
Figure 3. The ratio of the number of person years on ART 
under PrEP compared to TasP (red line) with 95% confidence 
limits (green lines). Here PrEP reduces the risk of infection by 
62% (0.16%−78%).4 Red arrow: the incidence of infection in 
the control arm of PrEP trial in Botswana4 of 3.1%/year; blue 
arrow: nominal incidence of 20%/year. 
 We use this model to compare PrEP against TasP 
based on the results of a study carried out in Botswana4 
in which PrEP reduced the risk of infection by 62% 
(0.16%−78%). As shown in Figure 3, the incidence rate 
reported in the control arm of the trial was 3.1% per 
annum (red arrow) so that TasP rather than PrEP would 
result in about 30% fewer person-years on ART. If the 
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annual incidence were much higher at 20% per annum, 
say, (blue arrow) the data from the trial shows that TasP 
without PrEP would lead to 24% more person years on 
ART which would favour PrEP but it should be noted 
that the 95% confidence interval for this estimate is 
−4% to 75%) so that the estimate is not significantly 
different from zero (p > 0.05). 
Discussion 
This analysis suggests that PrEP is unlikely to lead to a 
reduction in the number of person years requiring ART 
unless the incidence of ART without PrEP is greater 
than about 5% per year and PrEP reduces the risk of 
infection by at least 50%.  
 Here we represent the risk as a step-function of time; 
since we have good data on the age-specific incidence 
of infection from many epidemics we could generalize 
the argument to apply in such cases. Note that the 
balance between the two approaches will depend on the 
duration of risk, here taken to be 10 years, and it will be 
important to investigate further the way in which this 
affects the results. 
 Although the adult incidence of infection in nearly 
all countries of the world is less than 5% per year, and 
often very much less, incidence rates of more than 10% 
have been reported among young women in southern 
Africa22,23 and among intravenous-drug user and 
commercial sex workers. In such situations PrEP could 
have an important role to play, provided the reduction in 
the risk of infection is greater than about 50%. The 
PrEP study in Botswana reported low rates of retention 
partly because of nausea, vomiting and dizziness 
brought on by the use of ART and if these problems can 
be overcome it may be possible to get a higher retention 
rate under PrEP. 
 We have excluded the impact of treatment on 
transmission. Under either approach widespread 
treatment would reduce incidence and this would swing 
the balance further in favour of TasP and against PrEP. 
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